Management
Yves Cornellier, President and Chief Executive Officer
Yves is a veteran marketing and sales professional with more than 25 years in the healthcare industry and extensive experience negotiating licensing and collaboration agreements with large pharmaceutical companies, biotechnology companies and institutions. Prior to joining Alethia, Yves was Senior Vice President, Business Development for LAB International Inc. since October 2003, subsequent to the acquisition of Seyvika Pharmaceuticals for which he was the founder. Prior, he held the position of Vice-President, Business Development and Commercialization at Theratechnologies, and also held the position of Director of Business Development and Senior Marketing Manager, Pharmaceuticals Product Division, for Abbott Laboratories Ltd. He also had the opportunity to work for Glaxo Canada and Miles Laboratories Canada in management positions of increasing responsibility including sales management, marketing, business unit management and strategic development. Yves has been and still is a member of the Board of Directors of several organizations.
Mario Filion, Ph.D., Executive Vice-President and Chief Scientific Officer
Mario was involved in the creation of Alethia in 2002. In his current position, he oversees Alethia's operations including research and development, pre-clinical studies, collaborations with Universities . Prior, he acted as President of the Clinical Genomics Unit at SignalGene. Prior to joining SignalGene, Mario served as Director, Biotechnology at T2C2/Bio, a leading venture capital fund in Montréal. Earlier in his career, he acted as Director, Molecular Genetics of Algène Biotechnologies. Mario holds a Ph.D. degree in molecular biology from l'Université de Montréal and was an NSERC and FRSQ post-doctoral fellow at McGill University.
Gilles Tremblay, Ph.D., Director, drug discovery
Gilles is responsible for drug discovery at Alethia. Gilles started his career as group leader, drug development unit at SignalGene. He has devoted his career to research and discovery of new drugs for the treatment of cancer where he participated in the development of new antiestrogens as well as supervised the preclinical development of novel anti-angiogenic factors. Gilles holds a Ph.D. degree in biochemistry from McGill University and was a post-doctoral fellow at the Molecular Oncology Group, McGill University Health Center.
Anna Moraitis, Ph.D., Associate-director, product development
Anna is responsible for the development of biotherapeutics at Alethia. She started at Alethia as an NSERC industrial post-doctoral fellow. She was involved in the validation of genes involved in the differentiation of osteoclasts and in ovarian tumor evolution. She holds a Ph.D degree in biochemistry from McGill University
